Sanofi fights off Novo Nordisk to acquire Ablynx as Biotech M&A activity booms with more to come
French pharmaceutical firm Sanofi beat Danish rival Novo Nordisk in a bidding war to acquire a Belgian biopharma firm named Ablynx, agreeing a deal to buy the company for €3.9bn, a 48 per cent higher offer than its competitor.
Ablynx rebuffed Novo Nordisk’s offer to buy the business for €2.6 billion earlier this month, saying the offer “fundamentally undervalues Ablynx and its strong prospects for continued growth and value creation.”
The main attraction for Novo was Ablynx’s experimental drug Caplacizumab, designed to treat a rare blood disorder named thrombotic thrombocytopenic purpura, which would have complemented Novo’s line-up of blood products focused on haemophilia.
The deal is another sign of accelerating mergers and acquisition activity in the global biotech sector. This month has seen a surge in major biotech deals, with Sanofi also buying Bioverativ (a firm that focuses on blood disorders) for a cool $11.6 billion last week, as well as Celgene paying $9 billion for cancer specialist Juno Therapeutics earlier in January.
Last year, mergers and acquisitions in the ‘life sciences’ industry (which includes biotech, food processing, biomedical devices, pharmaceuticals etc) totalled $200 billion, led by Johnson & Johnson’s $30 billion acquisition of Actelion and Gilead Science’s grab of Kite Pharma, with almost $12 billion.
Consultancy firm Ernst & Young argued in a report this month that 2018’s activity should exceed last year’s total.
E&Y said in a statement: “We expect that in 2018 the total value of life sciences M&A should once again surpass US$200 billion, as the fundamental drivers of competition and pricing pressure in core therapeutic battlefields intensify, as the downstream effects of US tax reform materialize and as new sources of capital from outside the traditional centers of life sciences M&A increasingly join the fray.
Related: Hot stocks to watch for 2018
Want to learn more about the markets and how to become a better investor?
Download the Invstr App now.
Invstr is a technology platform, not a registered broker-dealer or investment adviser. Invstr does not offer its own recommendations of any security or provide its own research to any user regarding any security transaction or order.
Please note, investing involves risk and investments may lose value. Past performance does not guarantee future results.
Brokerage services are provided by the following:
US-traded securities, including fractional trading, are provided to Invstr users by DriveWealth LLC, a regulated member of FINRA/SIPC. DriveWealth may not establish investment accounts to residents of certain jurisdictions. For more information, including disclaimers, risk and transaction fees click here.
India account traded securities are provided by SIC Stocks & Services PVT Ltd. SIC does not make any personal recommendations to buy, sell or otherwise deal in investments. Investors make their own investment decisions. The services and securities provided by SIC may not be suitable for all customers and, if you have any doubts, you should seek advice from an independent financial adviser. For more information and disclaimers, click here.